Utilizing a pancreatic cancer-specific promoter such as the Mucin1 Promoter (MUC1) to control E1A expression also enhanced the replication selectivity in pancreatic cancer.44 Systemic administration of oncolytic adenoviruses has favorable toxicity profiles in cancer patients. Here, MUC1 is linked to familial pancreatic carcinoma.